Glimestar-PM1 Tablet ER
Marketer
Mankind Pharma Ltd
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Pioglitazone (15mg)
Overview Glimestar-PM1 Tablet ER
Diabetic patients using Glimestar-PM1 ER tablets should be aware that this extended-release combination medication aids in glycemic management. Its use complements a healthy diet and exercise regimen to optimize blood glucose control in adult type 2 diabetics. The medication enhances insulin effectiveness, resulting in reduced blood sugar. Always adhere to your physician's prescribed dosage and frequency, taking it with food to minimize gastrointestinal discomfort. Missed doses should be taken promptly unless nearing the next scheduled dose; never double the dose to compensate. Overdosing can cause dangerously low blood sugar (hypoglycemia). Concurrent use with other antidiabetic medications, alcohol consumption, or meal skipping may increase hypoglycemia risk; regular blood glucose monitoring is crucial. Common side effects encompass nausea, diarrhea, abdominal pain, headaches, bone fractures, and respiratory infections. Prior to commencing treatment, individuals with pre-existing kidney, liver, or heart conditions should consult their doctor, as should pregnant or lactating women. Baseline kidney function tests are typically conducted before treatment initiation. Limiting alcohol intake is advisable, as excessive consumption might exacerbate adverse reactions.
Primary Ingredients of Glimestar-PM1 Tablet ER
No text was provided to rewrite.
Uses of Glimestar-PM1 Tablet ER
Managing Type 2 Diabetes
Major Benefits of Glimestar-PM1 Tablet ER:
Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Glimestar-PM1 Tablet ER whole; avoid crushing, chewing, or breaking it. Administer this extended-release tablet with a meal.
Common Side effects of Glimestar-PM1 Tablet ER:
- Hypoglycemia (low blood glucose level)
- Headache
- Nausea
- Diarrhea
- Dizziness
- Vomiting
- Anemia (low number of red blood cells)
- Weakness
- Sinus infection
How to use Glimestar-PM1 Tablet ER:
Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Glimestar-PM1 Extended-Release tablets should be administered with a meal.
How Glimestar-PM1 Tablet ER works:
Glimestar-PM1 Extended-Release tablets combine glimepiride, metformin, and pioglitazone—three distinct antidiabetic agents. These medications employ different modes of action to optimize blood sugar management when monotherapy or dual therapy proves insufficient. Glimepiride, a sulfonylurea, stimulates pancreatic insulin release, thus reducing blood glucose levels. Metformin, a biguanide, acts by decreasing hepatic glucose production, slowing intestinal glucose absorption, and enhancing insulin responsiveness. Pioglitazone, a thiazolidinedione, further improves insulin sensitivity.
SAFETY ADVICE
AlcoholUNSAFE
Combining Glimestar-PM1 Tablet ER and alcohol is unsafe.
PregnancyCONSULT YOUR DOCTOR
The extended-release Glimestar-PM1 tablet may pose risks during pregnancy. While human data is scarce, animal research indicates potential harm to the unborn child. A physician will assess the advantages against possible dangers prior to prescribing. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
Extended-release Glimestar-PM1 tablets are likely not safe for breastfeeding mothers. Available human data indicates potential transfer of the medication into breast milk, posing a risk to the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these blood sugar imbalances.
KidneyCAUTION
Exercise caution when administering Glimestar-PM1 Tablet ER to individuals with impaired kidney function; dosage modification may be necessary. Consult a physician for guidance. Glimestar-PM1 Tablet ER is contraindicated in patients exhibiting severe kidney disease. Routine monitoring of renal function is recommended during treatment.
LiverCAUTION
Patients with liver impairment should exercise caution when using Glimestar-PM1 Tablet ER; dosage modification may be necessary. Consult a physician for guidance. Glimestar-PM1 Tablet ER is contraindicated in individuals with severe hepatic dysfunction.
What if you forget to take Glimestar-PM1 Tablet ER :
Should you forget a dose of Glimestar-PM1 Extended-Release Tablet, take it immediately. Nevertheless, if your next dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Glimestar-PM1 Tablet ER
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently